These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36551450)

  • 1.
    Principe L; Di Bella S; Conti J; Perilli M; Piccirilli A; Mussini C; Decorti G
    Antibiotics (Basel); 2022 Dec; 11(12):. PubMed ID: 36551450
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Karlowsky JA; Hackel MA; McLeod SM; Miller AA
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0078122. PubMed ID: 36005804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant
    Karruli A; Migliaccio A; Pournaras S; Durante-Mangoni E; Zarrilli R
    Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance.
    Findlay J; Poirel L; Bouvier M; Nordmann P
    J Glob Antimicrob Resist; 2022 Sep; 30():445-450. PubMed ID: 35618210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii.
    Seifert H; Müller C; Stefanik D; Higgins PG; Miller A; Kresken M
    J Antimicrob Chemother; 2020 Sep; 75(9):2616-2621. PubMed ID: 32516359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant
    Petropoulou D; Siopi M; Vourli S; Pournaras S
    Front Cell Infect Microbiol; 2021; 11():814530. PubMed ID: 35127562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
    Kaye KS; Shorr AF; Wunderink RG; Du B; Poirier GE; Rana K; Miller A; Lewis D; O'Donnell J; Chen L; Reinhart H; Srinivasan S; Isaacs R; Altarac D
    Lancet Infect Dis; 2023 Sep; 23(9):1072-1084. PubMed ID: 37182534
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    O'Donnell J; Tanudra A; Chen A; Newman J; McLeod SM; Tommasi R
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0080023. PubMed ID: 38092671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China.
    Yang Q; Xu Y; Jia P; Zhu Y; Zhang J; Zhang G; Deng J; Hackel M; Bradford PA; Reinhart H
    J Antimicrob Chemother; 2020 Jul; 75(7):1833-1839. PubMed ID: 32306049
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    McLeod SM; Moussa SH; Hackel MA; Miller AA
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988095
    [No Abstract]   [Full Text] [Related]  

  • 11. Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting
    McLeod SM; O'Donnell JP; Narayanan N; Mills JP; Kaye KS
    Future Microbiol; 2024; 19(7):563-576. PubMed ID: 38426849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug Resistant
    Velmurugan H; Venkatesan S; Meles HN; Neelambaram K; Thangaraju P
    Infect Disord Drug Targets; 2024; 24(6):e220124225835. PubMed ID: 38258766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of
    Moussa SH; Shapiro AB; McLeod SM; Iyer R; Carter NM; Tsai Y-K; Siu LK; Miller AA
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0066523. PubMed ID: 37843305
    [No Abstract]   [Full Text] [Related]  

  • 14.
    O'Donnell J; Tanudra A; Chen A; Miller AA; McLeod SM; Tommasi R
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0031223. PubMed ID: 38092676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of sulbactam-durlobactam in treating carbapenem-resistant Acinetobacter infections.
    Bassetti M; Giacobbe DR; Castaldo N; Vena A
    Curr Opin Infect Dis; 2024 Dec; 37(6):547-553. PubMed ID: 39259710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex.
    O'Donnell JP; Bhavnani SM
    Clin Infect Dis; 2023 May; 76(Suppl 2):S202-S209. PubMed ID: 37125469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Activity of Sulbactam-Durlobactam against Carbapenem-Resistant
    Segatore B; Piccirilli A; Cherubini S; Principe L; Alloggia G; Mezzatesta ML; Salmeri M; Di Bella S; Migliavacca R; Piazza A; Meroni E; Fazii P; Visaggio D; Visca P; Cortazzo V; De Angelis G; Pompilio A; Perilli M
    Antibiotics (Basel); 2022 Aug; 11(8):. PubMed ID: 36010006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
    Zhao C; Xie W; Zhang W; Ye Z; Wu H
    Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections.
    Watkins RR; Bonomo RA
    Clin Infect Dis; 2023 May; 76(Suppl 2):S163-S165. PubMed ID: 37125465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulbactam-durlobactam: A novel β-lactam-β-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections.
    El-Ghali A; Kunz Coyne AJ; Caniff K; Bleick C; Rybak MJ
    Pharmacotherapy; 2023 Jun; 43(6):502-513. PubMed ID: 37052117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.